With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

GP in many parts of England are having explain to eligible patients that tirzepatide (Mounjaro) cannot be prescribed in ...

In a new TikTok video, the consultant and professor explains who's really eligible and why BMI isn't the full story ...

Novo Nordisk launches Wegovy in India, expanding GLP-1 obesity drug market. The product competes with Eli Lilly's Mounjaro ...

With the weight-loss blockbuster drug Wegovy, now in India, renowned endocrinologist and diabetologist Dr. Ambrish Mithal ...

Experts have issued GPs with crucial guidance on weight loss jabs to avoid deadly complications, as the injections are ...

Mounjaro has been approved for both type 2 diabetes and weight loss, but access will be limited by strict eligibility ...

FAT jabs are shrinking supermarket sales, with grocery volumes falling 0.4% year-on-year, new figures reveal. Popular Ozempic ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could ...

The Weight Loss Revolution— that’s released on Wednesday provides a detailed insight into these weight management drugs and ...

I thought it was going to be another diet trend but the food noises got switched off,' said Ms Ogley, who used the injections ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...